367.18MMarket Cap-7370P/E (TTM)
13.770High12.940Low218.43KVolume13.100Open13.000Pre Close2.94MTurnover1.13%Turnover RatioLossP/E (Static)26.96MShares24.00052wk High2.04P/B264.10MFloat Cap7.91052wk Low--Dividend TTM19.39MShs Float24.000Historical High--Div YieldTTM6.39%Amplitude7.910Historical Low13.482Avg Price1Lot Size
Alto Neuroscience Stock Forum
Core business and technology:
Personalized Medication: Alto Neuroscience’s goa...
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet